Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Kenji Mamoto, Kentaro Inui, Tadashi Okano, Yuko Sugioka, Masahiro Tada, Tatsuya Koike & Hiroaki Nakamura. (2017) Incidence rate of falls and its risk factors in patients with rheumatoid arthritis compared to controls: Four years of the TOMORROW study. Modern Rheumatology 27:1, pages 8-14.
Read now
Read now
Alberto Migliore, Emanuele Bizzi, Colin Gerard Egan, Mauro Bernardi & Lea Petrella. (2015) Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. Therapeutics and Clinical Risk Management 11, pages 1325-1335.
Read now
Read now
Articles from other publishers (7)
Antonietta Stellavato, Odile Francesca Restaino, Valentina Vassallo, Rosario Finamore, Carlo Ruosi, Elisabetta Cassese, Mario De Rosa & Chiara Schiraldi. (2019) Comparative Analyses of Pharmaceuticals or Food Supplements Containing Chondroitin Sulfate: Are Their Bioactivities Equivalent?. Advances in Therapy 36:11, pages 3221-3237.
Crossref
Crossref
Sytske Anne Bergstra, Lai-Ling Winchow, Elizabeth Murphy, Arvind Chopra, Karen Salomon-Escoto, João Eurico Fonseca, Cornelia F Allaart & Robert B M Landewé. (2019) How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies. Annals of the Rheumatic Diseases 78:1, pages 25-30.
Crossref
Crossref
Astrid Wiens, Helena Hiemisch Lobo Borba, Letícia Paula Leonart, Fernanda Stumpf Tonin, Laiza Maria Steimbach, Ariane Gonçalves Silva de Araújo, Thais Piazza, Vinicius Lins Ferreira & Roberto Pontarolo. (2018) Treatment interruption of biological drugs and tofacitinib in rheumatoid arthritis: A systematic review of case reports. Brazilian Journal of Pharmaceutical Sciences 54:4.
Crossref
Crossref
Rishi J. Desai, Kylie J. Thaler, Peter Mahlknecht, Gerald Gartlehner, Marian S. McDonagh, Bita Mesgarpour, Alireza Mazinanian, Anna Glechner, Chandrasekar Gopalakrishnan & Richard A. Hansen. (2016) Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review. Arthritis Care & Research 68:8, pages 1078-1088.
Crossref
Crossref
Alberto Migliore, Emanuele Bizzi, Lea Petrella, Vincenzo Bruzzese, Maurizio Cassol & Davide Integlia. (2016) The Challenge of Treating Early-Stage Rheumatoid Arthritis: The Contribution of Mixed Treatment Comparison to Choosing Appropriate Biologic Agents. BioDrugs 30:2, pages 105-115.
Crossref
Crossref
Leslie R Harrold, George W Reed, Joel M Kremer, Jeffrey R Curtis, Daniel H Solomon, Marc C Hochberg & Jeffrey D Greenberg. (2015) The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Annals of the Rheumatic Diseases 74:2, pages 430-436.
Crossref
Crossref
Petra Baji, Márta Péntek, László Czirják, Zoltán Szekanecz, György Nagy, László Gulácsi & Valentin Brodszky. (2014) Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. The European Journal of Health Economics 15:S1, pages 53-64.
Crossref
Crossref